Ceapro Inc.
TSX VENTURE : CZO

Ceapro Inc.

November 13, 2014 11:02 ET

Ceapro Engages Jenene Thomas Communications, LLC as Strategic Investor Relations and Corporate Communications Advisor

EDMONTON, ALBERTA--(Marketwired - Nov. 13, 2014) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the Company has engaged Jenene Thomas Communications, LLC to provide strategic investor relations and communication advisory services.

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "We are pleased to announce the appointment of Jenene Thomas Communications to lead and execute a robust, strategic investor relations and financial communications program with the goal of raising the visibility and awareness of the Company. Ceapro looks forward to developing a strong partnership with Jenene Thomas Communications as we work to effectively communicate our strategic objectives, expand our footprint with the investment community and seek to maximize shareholder value."

Jenene Thomas, founder and Chief Executive Officer of Jenene Thomas Communications, commented, "We look forward to working with the Ceapro management team and are wholly committed to strategic and operational excellence in designing a specialized, fully integrated investor relations and corporate communications strategy for the Company. Ceapro has deep expertise and a solid reputation as an innovative formulator and advanced processor of unique natural-based products. We are excited to establish their fundamental financial communications program to further build on the Company's science and clinical evidence based biotechnology development programs."

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

About Jenene Thomas Communications, LLC

Jenene Thomas Communications, LLC is a dedicated biopharmaceutical advisory firm that specializes in designing and executing fully integrated Investor Relations, Communications and Corporate Strategy programs with the mission of helping clients achieve their near and long term goals while building visibility and establishing credibility. With nearly 20 years of in-house biotech investor relations, including C-level experience, the firm is committed to building concise, fundamental programs that deliver results. Jenene Thomas Communications applies best practices with creativity while leveraging a deep network of key life science decision makers to pursue its commitment of achieving each client's mission and vision. For more information, please visit www.jenenethomascommunications.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • INVESTOR AND MEDIA CONTACT:
    Jenene Thomas Communications, LLC
    Jenene Thomas
    Investor Relations and Corporate Communications Advisor
    (US): 908-938-1475
    jenene@jenenethomascommunications.com